Observational studyAdvances in therapy2023

Safety and Effectiveness of SB2 (Infliximab Biosimilar) in Adult Patients with Immune-Mediated Inflammatory Diseases: A Post-Marketing Surveillance in Korea.

Dong W Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.